494 results on '"O'Dorisio T"'
Search Results
2. Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogs.
3. Consensus statement: Octreotide dose titration in secretory diarrhea: Diarrhea management consensus development panel
4. Minimal model analysis of insulin sensitivity and glucose-mediated glucose disposal in Type 1 (insulin-dependent) diabetic pancreas allograft recipients
5. Chef cells possess somatostatin receptors regulated by secretagogues acting through the calcium or cAMP pathway
6. Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs
7. Sandostatin®: Assay and Efficacy in VIPoma and Insulinoma
8. Tumors of the Gastroenteropancreatic Axis
9. Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
10. Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study
11. Consensus
12. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl : Analyses of Two Phase 3 Studies in Carcinoid Syndrome
13. Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl
14. Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
15. Prologue
16. Future Directions
17. 1316P - Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study
18. Is GIP a glucagon cell constituent?
19. Pancreatic polypeptide in acute pancreatitis and small-bowel infarction in dogs
20. Exacerbation of diarrhea after iodinated contrast agents in a patient with VIPoma
21. The effects of carbohydrate-enriched meals on glucose turnover and metabolic clearance rates of glucose in Type 2 diabetic patients
22. Effects of pancreatic polypeptide and vasoactive intestinal polypeptide on rat ileal and colonic water and electrolyte transportin vivo
23. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide
24. Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR
25. Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
26. High-grade neuroendocrine carcinoma of the uterine cervix: Outcomes and the role of chemotherapy.
27. A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome.
28. A single-center retrospective analysis: The correlation of grade, chromogranin-A, SST2 IHC stains, and OctreoScan imaging in small bowel and pancreatic NETs.
29. Gastrointestinal neuroendocrine tumors: Concordance of SST2 and chromogranin A immunohistochemical staining in relation to primary site of tumor origin: A single-center retrospective analysis.
30. Neuroendocrine Tumors in Children and Young Adults
31. Neuroendocrine tumors in children and young adults: Incidence, survival, and prevalence in the United States
32. Phase I trial of molecularly targeted, radiolabeled somatostatin analog in children and young adults with recurrent or progressive solid tumors
33. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer
34. An open-label phase II clinical trial of PTK787 in patients with progressive neuroendocrine cancer
35. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR
36. An open-label phase II study evaluating the safety and efficacy of PTK787 in patients with progressive metastatic neuroendocrine cancer
37. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study
38. Octreotide acetate (LAR) dose effect on plasma octreotide levels: Impact on neuroendocrine tumor management
39. Growing vascular endothelial cells express somatostatin subtype 2 receptors
40. Desaturation Function Does Not Decline after Menopause in Human Females
41. Procainamide-induced chronic inflammatory demyelinating polyradiculoneuropathy
42. Serum Insulin and Glucose Concentrations in People at Risk for Type II Diabetes: A comparative study of African Americans and Nigerians
43. Effects of Tolbutamide on Growth and Body Composition of Nondiabetic Children with Cystic Fibrosis
44. The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients
45. Physiological and pharmacological stimulation of pancreatic islet hormone secretion in type I diabetic pancreas allograft recipients
46. Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin): II. Effect on pancreatic and thyroid hormone
47. Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (Sandostatin): I. An open-label pilot study
48. Vasoactive Intestinal Peptide Receptors in Human Platelet Membrane. Characterization of Binding and Functional Activity.
49. Characterization of Vasoactive Intestinal Peptide Receptors in Nervous and Immune Systemsa.
50. Somatostatin and Analogues in the Treatment of VIPoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.